Can a new drug erase the last traces of leukemia?

This phase 2 trial is testing whether adding venetoclax, a pill taken daily for 12 months, can reduce the number of leukemia stem cells that remain in the bone marrow of people with chronic myeloid leukemia (CML) who are already in deep molecular remission on standard TKI therapy. The goal is to see if venetoclax can target these persisting stem cells, which are thought to be the reason the disease can return after stopping TKI treatment. The study will also monitor quality of life and changes in BCR::ABL1 transcript levels over time. Participants must be adults with chronic-phase CML and typical BCR::ABL1 transcripts, and must have stored DNA from their initial diagnosis.